Lv21
190 积分 2025-04-14 加入
Pediatric Developmental Drug Toxicity: Description of Juvenile Animal Studies in US FDA Prescribing Information and Assessing the Need for New Approach Methodologies
12天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
13天前
已完结
A CDER Perspective: Landscape of New Approach Methodologies (NAMs) submitted in Drug Development Programs
1个月前
已完结
Impurity Qualification Thresholds: An IQ Survey on Emerging Industry Experience with Health Authority Feedback
1个月前
已完结
Application of new approach methodologies for nonclinical safety assessment of drug candidates
1个月前
已完结
Nutritional and Anthropometric Indices in Children Receiving Haemodiafiltration vs Conventional Haemodialysis - The HDF, Heart and Height (3H) Study
1个月前
已关闭
Nutritional and Anthropometric Indices in Children Receiving Haemodiafiltration vs Conventional Haemodialysis - The HDF, Heart and Height (3H) Study
1个月前
已关闭
Considerations of non-human primate use in nonclinical toxicity study package for oncology therapeutics with well-characterized target in supports of 3Rs – an IQ DruSafe industry survey
2个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
3个月前
已完结
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
3个月前
已完结
皖公网安备34019202002308
